1. Medtech Insight
  2. >>Archive

In Brief

Brief summaries of recent developments in the medical device industry.

· Biomet Inc.’s (Warsaw, IN)Biomet 3i dental reconstructive device subsidiary has introduced a new dental implant that employs nanotechnology, the NanoTite Implant. The implant, based on Biomet 3i’s OSSEOTITE Implant, incorporates added deposits of nano-scale calcium phosphate crystals to approximately 50% of the surface. According to preclinical studies, these nano-scale deposits create a complex surface on the implant that appears to play a key role in how the implant bonds with the bone. Human bone recognizes calcium phosphate as biologically natural, allowing the bone and implant to bond during healing. Dental implants replace single or multiple missing teeth due to cavities, decay, trauma, or disease and are designed to help preserve bone structure and natural facial contours. The 2007 dental reconstructive device market is estimated to be approximately $625 million in the U.S. and exceeds $2 billion worldwide, growing at an annual rate of 15%-17%, according to Biomet.

· Spine arthroplasty company Impliant Inc. (Princeton, NJ) has received CE Mark approval for its TOPS-on-Fusion System, the world’s first total posterior motion preservation device that integrates lumbar fusion with...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.